Danyelza

Chemical Namenaxitamab-gqgk
Dosage FormInjection (intravenous; 40 mg/10 mL, 4 mg/mL)
Drug ClassMonoclonal antibodies
SystemNervous
CompanyY-mAbs Therapeutics, Inc.
Approval Year2020

Indication

  • For the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.
Last updated on 12/18/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Danyelza (naxitamab-gqgk) Prescribing Information. 2020Y-mAbs Therapeutics, Inc. New York, NY